{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immediate+Release+%28IR%29+Formulation&page=3",
    "query": {
      "intervention": "Immediate Release (IR) Formulation",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 59,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immediate+Release+%28IR%29+Formulation&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immediate+Release+%28IR%29+Formulation&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T03:41:20.341Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02453022",
      "title": "A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Danirixin HBr 50 mg IR Tablet",
          "type": "DRUG"
        },
        {
          "name": "Danirixin FB 50 mg IR Tablet",
          "type": "DRUG"
        },
        {
          "name": "Prilosec (omeprazole) 40mg Delayed-Release capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "65 Years to 80 Years"
      },
      "enrollment_count": 18,
      "start_date": "2015-05-18",
      "completion_date": "2015-07-31",
      "has_results": false,
      "last_update_posted_date": "2018-07-24",
      "last_synced_at": "2026-10-02T03:41:20.341Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02453022"
    },
    {
      "nct_id": "NCT02003365",
      "title": "Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis of the Knee"
      ],
      "interventions": [
        {
          "name": "FX006 10 mg",
          "type": "DRUG"
        },
        {
          "name": "FX006 40 mg",
          "type": "DRUG"
        },
        {
          "name": "TCA IR 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2013-11",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-10-02T03:41:20.341Z",
      "location_count": 3,
      "location_summary": "Paducah, Kentucky • Duncansville, Pennsylvania • Dallas, Texas",
      "locations": [
        {
          "city": "Paducah",
          "state": "Kentucky"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02003365"
    },
    {
      "nct_id": "NCT02762370",
      "title": "Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis of the Knee",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "FX006 32 mg",
          "type": "DRUG"
        },
        {
          "name": "TCA IR 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2016-04",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-10-02T03:41:20.341Z",
      "location_count": 8,
      "location_summary": "Anaheim, California • El Cajon, California • North Hollywood, California + 5 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02762370"
    },
    {
      "nct_id": "NCT00914641",
      "title": "Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Thrombosis"
      ],
      "interventions": [
        {
          "name": "Apixaban IR",
          "type": "DRUG"
        },
        {
          "name": "Apixaban MR1",
          "type": "DRUG"
        },
        {
          "name": "Apixaban MR2",
          "type": "DRUG"
        },
        {
          "name": "Apixaban MR3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 16,
      "start_date": "2009-06",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2009-08-25",
      "last_synced_at": "2026-10-02T03:41:20.341Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00914641"
    },
    {
      "nct_id": "NCT02777554",
      "title": "A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Apremilast IR",
          "type": "DRUG"
        },
        {
          "name": "Apremilast XL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 144,
      "start_date": "2016-08-17",
      "completion_date": "2016-11-22",
      "has_results": true,
      "last_update_posted_date": "2021-07-22",
      "last_synced_at": "2026-10-02T03:41:20.341Z",
      "location_count": 2,
      "location_summary": "Daytona Beach, Florida • Madison, Wisconsin",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02777554"
    },
    {
      "nct_id": "NCT06477926",
      "title": "A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ABBV-668 IR",
          "type": "DRUG"
        },
        {
          "name": "ABBV-668 ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 25,
      "start_date": "2024-07-09",
      "completion_date": "2024-09-20",
      "has_results": false,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-10-02T03:41:20.341Z",
      "location_count": 1,
      "location_summary": "Grayslake, Illinois",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06477926"
    },
    {
      "nct_id": "NCT00364533",
      "title": "A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthroplasty"
      ],
      "interventions": [
        {
          "name": "Tapentadol IR (CG5503)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone HCL IR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 367,
      "start_date": "2006-10",
      "completion_date": "2007-12",
      "has_results": true,
      "last_update_posted_date": "2014-04-21",
      "last_synced_at": "2026-10-02T03:41:20.341Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 42 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00364533"
    },
    {
      "nct_id": "NCT04996264",
      "title": "Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Snakebites",
        "Envenoming",
        "Envenoming, Snake",
        "Envenomation, Snake"
      ],
      "interventions": [
        {
          "name": "Varespladib Methyl",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of care (SOC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophirex, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2021-08-15",
      "completion_date": "2023-06-08",
      "has_results": true,
      "last_update_posted_date": "2025-07-01",
      "last_synced_at": "2026-10-02T03:41:20.341Z",
      "location_count": 8,
      "location_summary": "Tucson, Arizona • Loma Linda, California • Jacksonville, Florida + 5 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04996264"
    },
    {
      "nct_id": "NCT02206607",
      "title": "Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "PF-04937319 IR MST",
          "type": "DRUG"
        },
        {
          "name": "PF-04937319 MR 1",
          "type": "DRUG"
        },
        {
          "name": "PF-04937319 MR 2",
          "type": "DRUG"
        },
        {
          "name": "PF-04937319 MR 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 39,
      "start_date": "2014-09",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2016-03-04",
      "last_synced_at": "2026-10-02T03:41:20.341Z",
      "location_count": 2,
      "location_summary": "High Point, North Carolina • San Antonio, Texas",
      "locations": [
        {
          "city": "High Point",
          "state": "North Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02206607"
    },
    {
      "nct_id": "NCT00782600",
      "title": "Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "suspension IR",
          "type": "DRUG"
        },
        {
          "name": "CR 1",
          "type": "DRUG"
        },
        {
          "name": "CR 2",
          "type": "DRUG"
        },
        {
          "name": "CR 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 16,
      "start_date": "2008-07",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2009-06-09",
      "last_synced_at": "2026-10-02T03:41:20.341Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00782600"
    }
  ]
}